Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 6 Alarmin release and sympathetic stress response synergize in poststroke atheroprogression. Alarmin release and sympathetic stress response synergize.

Published byCurtis Booth Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 6 Alarmin release and sympathetic stress response synergize in poststroke atheroprogression. Alarmin release and sympathetic stress response synergize."— Presentation transcript:

1 Fig. 6 Alarmin release and sympathetic stress response synergize in poststroke atheroprogression.
Alarmin release and sympathetic stress response synergize in poststroke atheroprogression. (A) Flow cytometric analysis of myeloid cellularity in femur bone marrow 24 hours after stroke compared to sham surgery. (B) Representative images of immunofluorescence staining for tyrosine hydroxylase (TH) in femoral bone marrow 24 hours after stroke and sham surgery. (C) Quantification of TH+ area after stroke compared to sham on femoral sections (U test, n = 7 per group). (D) WT mice received quantum dot (Qdot) nanocrystal injections in the femoral bone marrow 2 hours before stroke or sham surgery and were sacrificed 24 hours later (U test, n = 6 per group). Representative gating strategy for CD45+CD11b+ monocytes and Qdot+ myeloid cells in spleen after stroke or sham surgery. (E) Quantification of total Qdot+ myeloid cells in spleens after stroke compared to sham surgery (U test, n = 5 per group). (F) HCD-fed ApoE−/− mice were splenectomized (Splenect.) before stroke or sham surgery and analyzed 7 days after stroke for total monocyte cell counts and proinflammatory Ly6Chigh frequency in aortas 1 week after stroke. (G) Quantification of overall plaque area in aortic valves of splenectomized mice after stroke induction (U test, n = 6 to 8 per group). (H to J) WT mice received either sRAGE, β3-blocker SR59230, both combined, or vehicle treatment immediately after stroke, and bone marrow (BM) (H) and spleen (I and J) were analyzed by flow cytometry 24 hours later for the total myeloid (CD45+CD11b+) cell count and monocyte activation (percentage of MHCII+ monocytes; H test, n = 6 to 8 per group). (K) HCD-fed ApoE−/− mice received sRAGE, SR59230, combination therapy, or control treatment immediately after stroke. Bar graphs represent the flow cytometric analysis of CD45+CD11b+ monocyte cell count, the percentage of MHCII+ monocytes, and Ly6Chigh monocytes in aortas 1 week after stroke (H test, n = 7 to 8 per group). (L) Area under the curve analysis quantifying plaque load in five consecutive sections of aortic valve for HCD-fed ApoE−/− mice (H test, n = 5 to 6 per group). *P < 0.05, **P < 0.01. Stefan Roth et al., Sci Transl Med 2018;10:eaao1313 Published by AAAS

Download ppt "Fig. 6 Alarmin release and sympathetic stress response synergize in poststroke atheroprogression. Alarmin release and sympathetic stress response synergize."

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Novel function for interleukin-7 in dendritic cell development

Novel function for interleukin-7 in dendritic cell development
by Dior Kingston, Michael A

by Dior Kingston, Michael A
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.

Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.
PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions
Fig. 1 pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN-α and CXCL4. pDCs infiltrate the skin of SSc patients and spontaneously secrete.

Fig. 1 pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN-α and CXCL4. pDCs infiltrate the skin of SSc patients and spontaneously secrete.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.
CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA
Fig. 4. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist, on anemic rodents. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist,

Fig. 4. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist, on anemic rodents. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist,
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 5 A competent Fc is required for the antitumor immune response.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.
Fig. 7 pDCs are critical for the maintenance of skin fibrosis and for the presence of CXCL4 in the skin. pDCs are critical for the maintenance of skin.

Fig. 7 pDCs are critical for the maintenance of skin fibrosis and for the presence of CXCL4 in the skin. pDCs are critical for the maintenance of skin.
Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.

Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.

Similar presentations

Ads by Google